I dont think that is the case. I have been following the IMU story for some years (from the sidelines).
CHMs assets are superior to IMUs in respect to tech, market size and potentially efficacy. IMUs allogenic Azer cell therapy looks ok in respect to CRs but the durability of the response appears poor.
Unlike IMU, CEO of CHM is being quite specific in her commentary - 3 sets of data for CDH17 in the coming months. First drop shortly. Her comments that CHM may move from Phase 1B to Phase 2 early (for example mid way through the second dose escalation cohort) is also very telling...surely this means strong, early signs of efficacy.....
I dont think that is the case. I have been following the IMU...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $69.79K | 17.44M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 40 | 26298938 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9548289 | 12 |
View Market Depth
| Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |